ADMA Biologics (ADMA) to Release Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $112.80 million for the quarter.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $15.52 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics has a one year low of $5.08 and a one year high of $23.64. The business’s 50-day moving average price is $16.90 and its two-hundred day moving average price is $18.02. The company has a market capitalization of $3.67 billion, a P/E ratio of 55.43 and a beta of 0.75.

Analyst Ratings Changes

ADMA has been the subject of several recent research reports. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.